Bold, Krysten W.
Sharma, Akshika
Haeny, Angela
Gueorguieva, Ralitza
Buta, Eugenia
Baldassarri, Stephen
Lempert, Lauren
Krishnan-Sarin, Suchitra
O’Malley, Stephanie
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA054993, R01DA054993, R01DA054993, R01DA054993, R01DA054993, R01DA054993, R01DA054993, R01DA054993, R01DA054993)
National Institute on Alcohol Abuse and Alcoholism (K23AA028515)
National Center for Advancing Translational Sciences (5UL1TR001863, 5UL1TR001863)
Article History
Received: 21 December 2023
Accepted: 15 February 2024
First Online: 12 March 2024
Declarations
:
: Ethical approval for the human subjects procedures of this trial was obtained from the Yale University Institutional Review Board Human Investigation Committee (HIC approval #2000032211). Consent to participate will be obtained from participants.
: Not applicable.
: There are no conflicts of interest or competing interests related to this work. Unrelated to the submitted work, Dr. O’Malley reports being a member of the American Society of Clinical Psychopharmacology’s (ASCP’s) Alcohol Clinical Trials Initiative, supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Otsuka, Pear Therapeutics, Kinnov Therapeutics; Consultant/advisory board member, Alkermes, Dicerna; patent application with Novartis and Yale; DSMB member for NIDA Clinical Trials Network. Dr. Gueorguieva reports Royalties from Taylor & Francis for an academic book.